The histone deacetylase inhibitor panobinostat as a radiosensitiser in bladder cancer

The histone deacetylase inhibitor panobinostat as a radiosensitiser in bladder cancer

<p>Muscle invasive bladder cancer (MIBC) has a poor prognosis. Currently, therapy consists of radical radiotherapy or cystectomy with or without chemotherapy. The average age of patients with MIBC is high and older patients are less able to tolerate surgery or chemoradiation due to their impai...

Szczegółowa specyfikacja

Opis bibliograficzny
1. autor:	Groselj, B
Kolejni autorzy:	Kiltie, A
Format:	Praca dyplomowa
Język:	English
Wydane:	2014
Hasła przedmiotowe:	Oncology Biology

Podobne zapisy

Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression
od: Groselj, B, i wsp.
Wydane: (2013)

Radiosensitisation of bladder cancer cells by panobinostat is modulated by Ku80 expression.
od: Groselj, B, i wsp.
Wydane: (2013)

Histone deacetylase inhibitors as radiosensitisers: Effects on DNA damage signalling and repair
od: Groselj, B, i wsp.
Wydane: (2013)

Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair.
od: Groselj, B, i wsp.
Wydane: (2013)

Histone Deacetylases and Their Potential as Targets to Enhance Tumour Radiosensitisation
od: Jennifer Antrobus, i wsp.
Wydane: (2022-03-01)

The histone deacetylase inhibitor romidepsin spares normal tissues while acting as an effective radiosensitiser in bladder tumours in vivo
od: Paillas, S, i wsp.
Wydane: (2020)

Radiosensitisation in vivo by histone deacetylase inhibition with no increase in early normal tissue radiation toxicity
od: Groselj, B, i wsp.
Wydane: (2017)

Identification of novel strategies to radiosensitise tumour cells
od: Anbalagan, S
Wydane: (2014)

The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines.
od: Jan M Klein, i wsp.
Wydane: (2013-01-01)

Internalising radioimmunoconjugates to target KRas cancer cells for simultaneous radio-ligand therapy and radiosensitisation
od: Lourenço, J
Wydane: (2024)

The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression
od: Lin Xiao, i wsp.
Wydane: (2022-05-01)

The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers.
od: Sharma, N, i wsp.
Wydane: (2013)

Histone deacetylase inhibitor panobinostat induces antitumor activity in epithelioid sarcoma and rhabdoid tumor by growth factor receptor modulation
od: Anne Catherine Harttrampf, i wsp.
Wydane: (2021-07-01)

Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells.
od: Tao Yan-Fang, i wsp.
Wydane: (2015-01-01)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
od: Monica Phimmachanh, i wsp.
Wydane: (2020-10-01)

The HDAC Inhibitor Panobinostat Promotes Expression of Delta 133p53 Variants in TP53 Wild-type Bladder Cancer Cells
od: Groselj, B, i wsp.
Wydane: (2012)

Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma
od: AGM Mostofa, i wsp.
Wydane: (2021-12-01)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
od: Masumeh Sanaei, i wsp.
Wydane: (2019-01-01)

Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
od: Martina Korfei, i wsp.
Wydane: (2018-01-01)

Acetylation and Histone Deacetylase Inhibitors in Cancer
od: Madeleine S. Q. Kortenhorst, i wsp.
Wydane: (2006-01-01)

Histone Deacetylases and their Inhibitors in Cancer Epigenetics
od: Kelly N. Hassell
Wydane: (2019-11-01)

The Pan-Deacetylase Inhibitor Panobinostat Inhibits Growth of Hepatocellular Carcinoma Models by Alternative Pathways of Apoptosis
od: Pietro Di Fazio, i wsp.
Wydane: (2010-01-01)

Histone deacetylase inhibitor, panobinostat, exerts anti-proliferative effect with partial normalization from aberrant epigenetic states on granulosa cell tumor cell lines.
od: Yukiko Hazama, i wsp.
Wydane: (2022-01-01)

The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy
od: Guo Li, i wsp.
Wydane: (2020-09-01)

HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors
od: Farbod Shojaei, i wsp.
Wydane: (2022-01-01)

SET7/9-mediated methylation affects oncogenic functions of histone demethylase JMJD2A
od: Ruicai Gu, i wsp.
Wydane: (2023-10-01)

Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines
od: Zopf Steffen, i wsp.
Wydane: (2012-09-01)

Fluid-electrolyte homeostasis requires histone deacetylase function
od: Kelly A. Hyndman, i wsp.
Wydane: (2020-08-01)

Characterisation of the histone acetyltransferase KAT7 as a novel target for radiosensitisation
od: Bittner, M
Wydane: (2017)

Potential of histone deacetylase inhibitors for the therapy of ovarian cancer
od: Fengyi Guo, i wsp.
Wydane: (2022-11-01)

Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy
od: Bin Tu, i wsp.
Wydane: (2020-06-01)

Tetrahydroisoquinolines as novel histone deacetylase inhibitors for treatment of cancer
od: Danqi Chen, i wsp.
Wydane: (2016-01-01)

The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo
od: Liebes Leonard, i wsp.
Wydane: (2007-10-01)

Histone deacetylase inhibitors in multiple myeloma
od: Sarah Deleu, i wsp.
Wydane: (2009-06-01)

Clinical Toxicities of Histone Deacetylase Inhibitors
od: Richard L. Piekarz, i wsp.
Wydane: (2010-08-01)

The application of histone deacetylases inhibitors in glioblastoma
od: Rui Chen, i wsp.
Wydane: (2020-07-01)

Antidepressant Actions of Histone Deacetylase Inhibitors
od: Haggarty, Stephen J., i wsp.
Wydane: (2010)

Medicinal chemistry of histone deacetylase inhibitors
od: Ružić Dušan, i wsp.
Wydane: (2021-01-01)

Epigenetic drug screening defines a PRMT5 inhibitor–sensitive pancreatic cancer subtype
od: Felix Orben, i wsp.
Wydane: (2022-05-01)

Dietary fibre manipulation as a potential endogenous mechanism of radiosensitisation in bladder cancer
od: Then, CK
Wydane: (2022)